Quick Answer
CRESCENT BIOPHARMA, INC. reported Operating Income of -$152.63 million for fiscal year 2025.
CRESCENT BIOPHARMA, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$152.63M | -281.2% |
| 2024 | -$40.04M | -1.9% |
| 2023 | -$39.28M | +17.1% |
| 2022 | -$47.40M | +25.3% |
| 2021 | -$63.45M | -23.2% |
| 2020 | -$51.51M | +16.1% |
| 2019 | -$61.39M | -19.2% |
| 2018 | -$51.50M | -51.8% |
| 2017 | -$33.93M | -6.3% |
| 2016 | -$31.91M | -149.6% |
| 2015 | -$12.78M | -14.8% |
| 2014 | -$11.14M | -5.0% |
| 2013 | -$10.61M | -391.8% |
| 2012 | $3.64M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$25.89M | -883.8% | -23.1% |
| June 30, 2025 | -$21.03M | -103.0% | -776.7% |
| March 31, 2025 | -$2.40M | +78.4% | +8.8% |
| September 30, 2024 | -$2.63M | +73.2% | +74.6% |
| June 30, 2024 | -$10.36M | -16.0% | +6.8% |
| March 31, 2024 | -$11.12M | -1.6% | -13.3% |
| September 30, 2023 | -$9.81M | -11.9% | -9.9% |
| June 30, 2023 | -$8.93M | +33.1% | +18.4% |
- CRESCENT BIOPHARMA, INC. showed a decrease of -281.2% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, CRESCENT BIOPHARMA, INC.’s operating income has declined by 4298.9% (from $3.64 million to -$152.63 million).
- The most recent figure is from CRESCENT BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: